Capecitabine as Radiosensitising Agent in Neoadjuvant Treatment of Locally Advanced Resectable Rectal Cancer

• Status: Completed
• Trial end date: 2010-04-01
• Target enrollment: 0
• Participant gender: All

Summary

A Phase II study aimed to evaluate the efficacy and toxicity of preoperative chemoradiotherapy with capecitabine in locally advanced resectable rectal cancer.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Institute of Oncology Ljubljana
• Treatments: Capecitabine

Criteria

Inclusion Criteria:

• histologically verified adenocarcinoma of the rectum,

• resectable clinical stage II or III (IUCC TNM classification 2002);

• no prior radiotherapy and/or chemotherapy;

• World Health Organisation (WHO) performance status < 2;

• age at diagnosis of 18 or older;

• and adequate bone marrow, liver, renal and cardiac function (no history of ischemic heart disease).

Exclusion Criteria:

• A history of prior malignancy other than non-melanoma skin cancer or in situ carcinoma of the cervix